SHANGHAI – Sciclone Pharmaceuticals Inc. is one of a few U.S.-listed specialty pharma companies almost exclusively focused on the China market. CEO Friedhelm Blobel sits in Foster City, Calif. – to be close to investors and shareholders – but he frequently finds himself on a plane to China, the main market for Sciclone’s oncology, infectious disease and cardiovascular therapies.